Expression analysis of thrombospondin 2 in prostate cancer and benign prostatic hyperplasia

Experimental and Molecular Pathology

Volumn 94, Issue 3, 2013, Pages 438-444

  Matos, A R ^a   Coutinho Camillo, C M ^b   Thuler, L C S ^a,c   Fonseca, F P ^b   Soares, F A ^b   Silva, E A ^d   Gimba, E R ^a,e  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^b A C CAMARGO CANCER CENTER   (Brazil)

^c FEDERAL UNIVERSITY OF THE STATE OF RIO DE JANEIRO   (Brazil)

^d HOSPITAL UNIVERSITÁRIO PEDRO ERNESTO   (Brazil)

^e FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

Author keywords

Benign prostatic hyperplasia; Prostate cancer; Thrombospondin 2

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; THROMBOSPONDIN 2;

ARTICLE; BLOOD LEVEL; CANCER GROWTH; CANCER INVASION; CANCER RECURRENCE; CELL LINE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; DIAGNOSTIC TEST ACCURACY STUDY; DOWN REGULATION; EPITHELIUM; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATE SPECIFIC ANTIGEN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; STAINING; STROMA; TISSUE MICROARRAY; TISSUE SECTION; TRANSCRIPTION REGULATION; TUMOR CELL;

ADENOCARCINOMA; CELL LINE, TUMOR; DISEASE PROGRESSION; DNA, NEOPLASM; DOWN-REGULATION; EPITHELIAL CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; ROC CURVE; STROMAL CELLS; THROMBOSPONDINS; TISSUE ARRAY ANALYSIS;

EID: 84876309280     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2013.02.002     Document Type: Article

References (40)

1. Adams J.C. Thrombospondins: multifunctional regulators of cell interactions. Annual Review of Cell and Developmental Biology 2001, 17:25-51.
2. Alcaraz A., Hammerer P., Tubaro A., Schröder F.H., Castro R. Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review. European Urology 2009, 55(4):864-873.
3. Armstrong L.C., Bornstein P. Thrombospondins 1 and 2 function as inhibitors of angiogenesis. Matrix Biology 2003, 22(1):63-71.
4. Ayala G., Tuxhorn J.A., Wheeler T.M., Frolov A., Scardino P.T., Ohori M., Wheeler M., Spitler J., Rowley D.R. Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer. Clinical Cancer Research 2003, 9(13):4792-4801.
5. Bastian M., Steiner M., Schuff-Werner P. Expression of thrombospondin-1 in prostate-derived cell lines. International Journal of Molecular Medicine 2005, 15(1):49-56.
6. Bertin N., Clezardin P., Kubiak R., Frappart L. Thrombospondin-1 and -2 messenger RNA expression in normal, benign, and neoplastic human breast tissues: correlation with prognostic factors, tumor angiogenesis, and fibroblastic desmoplasia. Cancer Research 1997, 57(3):396-399.
7. Chandran U.R., Ma C., Dhir R., Bisceglia M., Lyons-Weiler M., Liang W., Michalopoulos G., Becich M., Monzon F.A. Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process. BMC Cancer 2007, 7:64.
8. Chijiwa T., Abe Y., Inoue Y., Matsumoto H., Kawai K., Matsuyama M., Miyazaki N., Inoue H., Mukai M., Ueyama Y., Nakamura M. Cancerous, but not stromal, thrombospondin-2 contributes prognosis in pulmonary adenocarcinoma. Oncology Reports 2009, 22(2):279-283.
9. Chughtai B., Lee R., Te A., Kaplan S. Role of inflammation in benign prostatic hyperplasia. Revista de Urología 2001, 13(3):147-150.
10. Ciocca D.R., Cuello-Carrión F.D., Natoli A.L., Restall C., Anderson R.L. Absence of caveolin-1 alters heat shock protein expression in spontaneous mammary tumors driven by Her-2/neu expression. Histochemistry and Cell Biology 2012, 137(2):187-194.
11. Cunha G.R., Hayward S.W., Dahiya R., Foster B.A. Smooth muscle-epithelial interactions in normal and neoplastic prostatic development. Acta Anatomica 1996, 155(1):63-72.
12. Cunha G.R., Hayward S.W., Wang Y.Z. Role of stroma in carcinogenesis of the prostate. Differentiation 2002, 70(9-10):473-485.
13. Danielsen J.M., Knudsen L.M., Dahl I.M., Lodahl M., Rasmussen T. Dysregulation of CD47 and the ligands thrombospondin 1 and 2 in multiple myeloma. British Journal of Haematology 2007, 138(6):756-760.
14. Dayyani F., Gallick G.E., Logothetis C.J., Corn P.G. Novel therapies for metastatic castrate-resistant prostate cancer. Journal of the National Cancer Institute 2011, 103(22):1665-1675.
15. Fitchev P.P., Wcislak S.M., Lee C., Bergh A., Brendler C.B., Stellmach V.M., Crawford S.E., Mavroudis C.D., Cornwell M.L., Doll J.A. Thrombospondin-1 regulates the normal prostate in vivo through angiogenesis and TGF-beta activation. Laboratory Investigation 2010, 90(7):1078-1090.
16. Hahn W., Ho S.-H., Jeong J.-G., Hahn E.-Y., Kim S., Yu S.S., Kim S., Kim J.-M. Viral vector-mediated transduction of a modified thrombospondin-2 cDNA inhibits tumor growth and angiogenesis. Gene Therapy 2004, 11:739-745.
17. Hawighorst T., Velasco P., Streit M., Hong Y.K., Kyriakides T.R., Brown L.F., Bornstein P., Detmar M. Thrombospondin-2 plays a protective role in multistep carcinogenesis: a novel host anti-tumor defense mechanism. EMBO Journal 2001, 20(11):2631-2640.
18. Ioachim E., Damala K., Tsanou E., Briasoulis E., Papadiotis E., Mitselou A., Charhanti A., Doukas M., Lampri L., Arvanitis D.L. Thrombospondin-1 expression in breast cancer: prognostic significance and association with p53 alterations, tumour angiogenesis and extracellular matrix components. Histology and Histopathology 2012, 27(2):209-216.
19. Koch M., Hussein F., Woeste A., Gründker C., Frontzek K., Emons G., Hawighorst T. CD36-mediated activation of endothelial cell apoptosis by an N-terminal recombinant fragment of thrombospondin-2 inhibits breast cancer growth and metastasis in vivo. Breast Cancer Research and Treatment 2011, 128(2):337-346.
20. Kodama J., Hashimoto I., Seki N., Hongo A., Yoshinouchi M., Okuda H., Kudo T. Thrombospondin-1 and -2 messenger RNA expression in invasive cervical cancer: correlation with angiogenesis and prognosis. Clinical Cancer Research 2001, 7(9):2826-2831.
21. LaTulippe E., Satagopan J., Smith A., Scher H., Scardino P., Reuter V., Gerald W.L. Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Research 2002, 62(15):4499-4506.
22. Laxman B., Morris D.S., Yu J., Siddiqui J., Cao J., Mehra R., Lonigro R.J., Tsodikov A., Wei J.T., Tomlins S.A., Chinnaiyan A.M. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Research 2008, 68:645.
23. Lopaczynski W., Hruszkewycz A.M., Lieberman R. Preprostatectomy: a clinical model to study stromal-epithelial interactions. Urology 2001, 57(4 Suppl. 1):194-199.
24. Noh Y.H., Matsuda K., Hong Y.K., Kunstfeld R., Riccardi L., Koch M., Oura H., Dadras S.S., Streit M., Detmar M. An N-terminal 80kDa recombinant fragment of human thrombospondin-2 inhibits vascular endothelial growth factor induced endothelial cell migration in vitro and tumor growth and angiogenesis in vivo. The Journal of Investigative Dermatology 2003, 121:1536-1543.
25. Oshika Y., Masuda K., Tokunaga T., Hatanaka H., Kamiya T., Abe Y., Ozeki Y., Kijima H., Yamazaki H., Tamaoki N., Ueyama Y., Nakamura M. Thrombospondin 2 gene expression is correlated with decreased vascularity in non-small cell lung cancer. Clinical Cancer Research 1998, 4(7):1785-1788.
26. Porkka K.P., Pfeiffer M.J., Waltering K.K., Vessella R.L., Tammela T.L., Visakorpi T. MicroRNA expression profiling in prostate cancer. Cancer Research 2007, 67(13):6130-6135.
27. Santin A.D., Zhan F., Bellone S., Palmieri M., Cane S., Bignotti E., Anfossi S., Gokden M., Dunn D., Roman J.J., O'Brien T.J., Tian E., Cannon M.J., Shaughnessy J., Pecorelli S. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. International Journal of Cancer 2004, 112(1):14-25.
28. Streit M., Stephen A.E., Hawighorst T., Matsuda K., Lange-Asschenfeldt B., Brown L.F., Vacanti J.P., Detmar M. Systemic inhibition of tumor growth and angiogenesis by thrombospondin-2 using cell based antiangiogenic gene therapy. Cancer Research 2002, 62:2004-2012.
29. Timms B.G., Hofkamp L.E. Prostate development and growth in benign prostatic hyperplasia. Differentiation 2011, 82(4-5):173-183.
30. Tomas D., Spajić B., Milosević M., Demirović A., Marusić Z., Kruslin B. Intensity of stromal changes predicts biochemical recurrence-free survival in prostatic carcinoma. Scandinavian Journal of Urology and Nephrology 2010, 44(5):284-290.
31. Tuxhorn J.A., Ayala G.E., Smith M.J., Smith V.C., Dang T.D., Rowley D.R. Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clinical Cancer Research 2002, 8:2912-2923.
32. Tuxhorn J.A., McAlhany S.J., Dang T.D., Ayala G.E., Rowley D.R. Stromal cells promote angiogenesis and growth of human prostate tumors in a differential reactive stroma (DRS) xenograft model. Cancer Research 2002, 62:3298-3307.
33. Vallbo C., Damber J.E. Thrombospondins, metallo proteases and thrombospondin receptors messenger RNA and protein expression in different tumour sublines of the Dunning prostate cancer model. Acta Oncologica 2005, 44(3):293-298.
34. Vallbo C., Wang W., Damber J.E. The expression of thrombospondin-1 in benign prostatic hyperplasia and prostatic intraepithelial neoplasia is decreased in prostate cancer. BJU International 2004, 93(9):1339-1343.
35. Vong S., Kalluri R. The role of stromal myofibroblast and extracellular matrix in tumor angiogenesis. Genes & Cancer 2011, 2(12):1139-1145.
36. Witkiewicz A.K., Whitaker-Menezes D., Dasgupta A., Philp N.J., Lin Z., Gandara R., Sneddon S., Martinez-Outschoorn U.E., Sotgia F., Lisanti M.P. Using the "reverse Warburg effect" to identify high-risk breast cancer patients: stromal MCT4 predicts poor clinical outcome in triple-negative breast cancers. Cell Cycle 2012, 11(6):1108-1117.
37. Yamashita M., Zhang X., Shiraishi T., Uetsuki H., Kakehi Y. Determination of percent area density of epithelial and stromal components in development of prostatic hyperplasia in spontaneously hypertensive rats. Urology 2003, 61(2):484-489.
38. You J., Cozzi P., Walsh B., Willcox M., Kearsley J., Russell P., Li Y. Innovative biomarkers for prostate cancer early diagnosis and progression. Critical Reviews in Oncology/Hematology 2010, 73:10-22.
39. Zhang L., Sun S.K., Shi L.X., Zhang X. Serum cytokine profiling of prostate cancer and benign prostatic hyperplasia using recombinant antibody microarray. Zhonghua Nan Ke Xue 2010, 16(7):584-588.
40. Zhao F.J., Han B.M., Yu S.Q., Xia S.J. Tumor formation of prostate cancer cells influenced by stromal cells from the transitional or peripheral zones of the normal prostate. Asian Journal of Andrology 2009, 11(2):176-182.